No Agreement Reached on Acquisition Price Between the Two Companies
RevMed to Release Key Clinical Trial Data This Year

It has been reported that Merck, the U.S. pharmaceutical company, has halted acquisition talks with Revolution Medicines (hereafter referred to as RevMed), a developer of new cancer drugs.

Merck Logo

Merck Logo

View original image

On January 25 (local time), The Wall Street Journal (WSJ) reported, citing sources familiar with the matter, that negotiations between Merck and RevMed broke down as the two parties failed to reach an agreement on the acquisition price.


Merck had initially been in talks to acquire RevMed recently. If the deal had gone through, the company’s valuation could have reached around 30 billion dollars (approximately 43 trillion won). However, sources stated that the negotiations collapsed as both sides could not agree on the acquisition price.


They added, however, that it is still possible for negotiations to resume in the future or for other potential acquirers interested in RevMed to emerge. RevMed is scheduled to release key clinical trial data for its pancreatic and colorectal cancer drug candidates in the first half of this year.


RevMed is developing new drugs targeting the RAS protein, which is known as a molecular cause of cancer. The company’s experimental therapies block this molecular pathway. Their aim is to suppress major cancers that have been difficult to treat, such as lung cancer, pancreatic cancer, and colorectal cancer.



RevMed’s drug candidates are regarded as showing potential to overcome these challenges. Mizuho Securities has projected that if the pancreatic cancer drug candidate proves its safety and efficacy, RevMed could effectively dominate this treatment field and generate global sales of 10 billion dollars (about 14 trillion won) by 2035.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing